Abstract

Parkinson's disease is a progressive neuropathological disorder that belongs to the class of synucleopathies, in which the protein alpha-synuclein is found at abnormally high concentrations in affected neurons. Its hallmark are intracellular inclusions called Lewy bodies and Lewy neurites. We here report the structure of cytotoxic alpha-synuclein fibrils (residues 1-121), determined by cryo-electron microscopy structure at a resolution of 3.4Å. Two protofilaments form a polar fibril composed of staggered β-strands. The backbone of residues 38 to 95, including the fibril core and the non-amyloid component region, are well resolved in the EM map. Residues 50-57, containing three of the mutation sites associated with familial synucleinopathies, form the interface between the two protofilaments and contribute to fibril stability. A hydrophobic cleft at one end of the fibril may have implications for fibril elongation, and invites for the design of molecules for diagnosis and treatment of synucleinopathies.

Data availability

The cryo-EM image data are available in the Electron Microscopy Public Image Archive, entry number EMPIAR-10195. The 3D map is available in the EMDB, entry number EMD-4276. The atomic coordinates are available at the PDB, entry number PDB 6FLT.

The following data sets were generated
    1. Guerrero-Ferreira R
    2. Taylor NMI
    3. Mona D
    4. Riek R
    5. Britschgi M
    6. Stahlberg H
    (2018) Structure of alpha-synuclein fibrils
    Publicly available at the Electron Microscopy Data Bank (accession no. EMD-4276).
    1. Guerrero-Ferreira R
    2. Taylor NMI
    3. Mona D
    4. Riek R
    5. Britschgi M
    6. Stahlberg H
    (2018) Structure of alpha-synuclein fibrils
    Publicly available at the Electron Microscopy Public Image Archive (accession no. EMPIAR-10195).

Article and author information

Author details

  1. Ricardo Guerrero-Ferreira

    Center for Cellular Imaging and NanoAnalytics (C-CINA), University of Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3664-8277
  2. Nicholas M I Taylor

    Center for Cellular Imaging and NanoAnalytics (C-CINA), University of Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0761-4921
  3. Daniel Mona

    Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Area/Neuroscience Discovery, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    Daniel Mona, Employed by Hoffmann-La Roche. There are no other competing interests to declare..
  4. Philippe Ringler

    Center for Cellular Imaging and NanoAnalytics (C-CINA), University of Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
  5. Matthias E Lauer

    Roche Pharma Research and Early Development, Chemical Biology, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    Matthias E Lauer, Employed by Hoffmann-La Roche. There are no other competing interests to declare..
  6. Roland Riek

    Laboratory of Physical Chemistry, ETH Zürich, Zürich, Switzerland
    Competing interests
    No competing interests declared.
  7. Markus Britschgi

    Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Area/Neuroscience Discovery, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    Markus Britschgi, Employed by Hoffmann-La Roche. There are no other competing interests to declare..
  8. Henning Stahlberg

    Center for Cellular Imaging and NanoAnalytics (C-CINA), University of Basel, Basel, Switzerland
    For correspondence
    Henning.Stahlberg@unibas.ch
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1185-4592

Funding

Swiss National Science Foundation (CRSII3_154461 and CRSII5_177195)

  • Ricardo Guerrero-Ferreira
  • Nicholas M I Taylor

Synapsis Foundation Switzerland

  • Henning Stahlberg

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2018, Guerrero-Ferreira et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 21,726
    views
  • 3,298
    downloads
  • 470
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ricardo Guerrero-Ferreira
  2. Nicholas M I Taylor
  3. Daniel Mona
  4. Philippe Ringler
  5. Matthias E Lauer
  6. Roland Riek
  7. Markus Britschgi
  8. Henning Stahlberg
(2018)
Cryo-EM structure of alpha-synuclein fibrils
eLife 7:e36402.
https://doi.org/10.7554/eLife.36402

Share this article

https://doi.org/10.7554/eLife.36402

Further reading

    1. Medicine
    2. Neuroscience
    Sophie Leclercq, Hany Ahmed ... Nathalie Delzenne
    Research Article

    Background:

    Alcohol use disorder (AUD) is a global health problem with limited therapeutic options. The biochemical mechanisms that lead to this disorder are not yet fully understood, and in this respect, metabolomics represents a promising approach to decipher metabolic events related to AUD. The plasma metabolome contains a plethora of bioactive molecules that reflects the functional changes in host metabolism but also the impact of the gut microbiome and nutritional habits.

    Methods:

    In this study, we investigated the impact of severe AUD (sAUD), and of a 3-week period of alcohol abstinence, on the blood metabolome (non-targeted LC-MS metabolomics analysis) in 96 sAUD patients hospitalized for alcohol withdrawal.

    Results:

    We found that the plasma levels of different lipids ((lyso)phosphatidylcholines, long-chain fatty acids), short-chain fatty acids (i.e. 3-hydroxyvaleric acid) and bile acids were altered in sAUD patients. In addition, several microbial metabolites, including indole-3-propionic acid, p-cresol sulfate, hippuric acid, pyrocatechol sulfate, and metabolites belonging to xanthine class (paraxanthine, theobromine and theophylline) were sensitive to alcohol exposure and alcohol withdrawal. 3-Hydroxyvaleric acid, caffeine metabolites (theobromine, paraxanthine, and theophylline) and microbial metabolites (hippuric acid and pyrocatechol sulfate) were correlated with anxiety, depression and alcohol craving. Metabolomics analysis in postmortem samples of frontal cortex and cerebrospinal fluid of those consuming a high level of alcohol revealed that those metabolites can be found also in brain tissue.

    Conclusions:

    Our data allow the identification of neuroactive metabolites, from interactions between food components and microbiota, which may represent new targets arising in the management of neuropsychiatric diseases such as sAUD.

    Funding:

    Gut2Behave project was initiated from ERA-NET NEURON network (Joint Transnational Call 2019) and was financed by Academy of Finland, French National Research Agency (ANR-19-NEUR-0003-03) and the Fonds de la Recherche Scientifique (FRS-FNRS; PINT-MULTI R.8013.19, Belgium). Metabolomics analysis of the TSDS samples was supported by grant from the Finnish Foundation for Alcohol Studies.

    1. Neuroscience
    Mohsen Alavash
    Insight

    Combining electrophysiological, anatomical and functional brain maps reveals networks of beta neural activity that align with dopamine uptake.